Inotiv, Inc. reports news as a contract research organization providing nonclinical and analytical drug discovery and development services, research models, and related products for pharmaceutical, chemical, medical device, and biomedical research customers. Its updates commonly address Discovery and Safety Assessment activity, Research Models and Services performance, quarterly and annual financial results, and business trends tied to discovery, preclinical, and translational research demand.
Company announcements also cover collaborations and technology additions such as human-relevant in vitro models, AI-assisted bioinformatics, and multi-omics analysis within Discovery & Translational Sciences. Other recurring items include conference-call schedules, operational business updates, cybersecurity incident notices, and corporate communications affecting Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Inotiv, Inc. (NASDAQ: NOTV) has announced that it will release its fiscal 2023 second quarter financial results, covering the period ending March 31, 2023, on May 11, 2023, following the market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. The call will be accessible via phone and online streaming through the Company’s Investor section.
Inotiv is a contract research organization that specializes in nonclinical and analytical drug discovery and development services. The firm aims to improve the efficiency and cost-effectiveness of bringing new medical products to market. The press release also highlights potential risks, including market changes and regulatory compliance, which could impact the Company’s operations and financial condition.
Inotiv (Nasdaq: NOTV) has been awarded the 2022 North American Customer Value Leadership Award by Frost & Sullivan for its excellence in bio-analytical testing services. The company specializes in contract research services and research products, providing comprehensive R&D solutions supported by experienced scientists and state-of-the-art facilities. Inotiv's drug discovery approach emphasizes client value through direct resource allocation, experienced scientific guidance, and innovative methodologies. The company is committed to enhancing its market position by strategically acquiring firms to boost revenues and client offerings, ensuring a client-first approach. This award highlights Inotiv's unique focus on elevating customer value, leading to improved satisfaction and retention.
Inotiv, Inc. (NASDAQ: NOTV) reported Q1 FY 2023 revenue of $122.8 million, up 45.8% from $84.2 million in Q1 FY 2022. Growth was driven by a $8.3 million increase in Discovery and Safety Assessment (DSA) revenue and $30.3 million in Research Models and Services (RMS) revenue, attributed to acquisitions and rising demand. However, the Company recorded a net loss of $(86.9 million), worsened by a $66.4 million non-cash goodwill impairment charge. Adjusted EBITDA fell to $(5.5 million). Inotiv reaffirmed FY 2023 guidance of at least $580 million in revenue and $75 million in Adjusted EBITDA.